ArticleFrontiers in bioengineering and biotechnology2025
More than just life and death: advances in imaging and analysis for 3D-bioprinted tissues.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence-assisted smart hydrogel bioinks in 3D bioprinting: design, optimization, and construct validation for functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D bioprinting is a fast-growing field with applications in both microphysiological systems and tissue engineering. However, the qualifications and definitions of success for 3D-bioprinted products are insufficient. We can further our characterization of 3D-bioprinting methods and finished products using new imaging techniques and analysis methods, including the use of AI tools. This multi-faceted approach can deepen our understanding of valuable technology by examining the effects of 3D bioprinting on cell identity, behavior and organelles. Defining a successful 3D-bioprinted product in addition to viability is crucial in the push toward using these models for drug screening or disease modeling, where robust and high-quality systems are required for meaningful data output.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.